Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Abstract Full Text (PDF, 171K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Forssmann, U. Articles by Baggiolini, M. Search for Related Content PubMed PubMed Citation Articles by Forssmann, U. Articles by Baggiolini, M. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Social Bookmarking                            What's this?

Brief Definitive Reports

Ulf Forssmann^*, Mariagrazia Uguccioni^*, Pius Loetscher^*,, Clemens A. Dahinden, Hanno Langen^||, Marcus Thelen^*, and Marco Baggiolini^*

From the ^* Theodor Kocher Institute, University of Bern, CH-3000 Bern, Switzerland; Division of Rheumatology, University Hospital, CH-3010 Bern, Switzerland; Institute of Immunology and Allergology, University Hospital, CH-3010 Bern, Switzerland; and ^|| Hoffmann-La Roche Ltd., Basel, Switzerland

	Abstract

Top Abstract Materials and Methods Results and Discussion References

 
A novel human CC chemokine consisting of 78 amino acids and having a molecular mass of 8,778.3 daltons (VVIPSPCCMF FVSKRIPENR VVSYQLSSRS TCLKAGVIFT TKKGQQ SCGD PKQEWVQRYM KNLDAKQKKA SPRARAVA) was isolated together with three minor COOH-terminally truncated variants with 73, 75, and 76 residues. The new chemokine was termed eotaxin-2 because it is functionally very similar to eotaxin. In terms of structure, however, eotaxin and eotaxin-2 are rather distant, they share only 39% identical amino acids and differ almost completely in the NH₂-terminal region. Eotaxin-2 induced chemotaxis of eosinophils as well as basophils, with a typically bimodal concentration dependence, and the release of histamine and leukotriene C₄ from basophils that had been primed with IL-3. In all assays, eotaxin-2 had the same efficacy as eotaxin, but was somewhat less potent. The migration and the release responses were abrogated in the presence of a monoclonal antibody that selectively blocks the eotaxin receptor, CCR3, indicating that eotaxin-2, like eotaxin, acts exclusively via CCR3. Receptor usage was also studied in desensitization experiments by measuring [Ca²⁺]_i changes in eosinophils. Complete cross-desensitization was observed between eotaxin-2, eotaxin and MCP-4 confirming activation via CCR3. No Ca²⁺ mobilization was obtained in neutrophils, monocytes and lymphocytes, in agreement with the lack of chemotactic responsiveness. Intradermal injection of eotaxin-2 in a rhesus monkey (100 or 1,000 pmol per site) induced a marked local infiltration of eosinophils, which was most pronounced in the vicinity of postcapillary venules and was comparable to the effect of eotaxin.

Leukocyte recruitment in inflammation and immunity is regulated by a large number of CXC and CC chemokines (1). In the past few years several new proteins of this class have been discovered and considerable information has been gained about the functions of the known ones. It has been shown in particular that the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3, and MCP-4) do not only act on monocytes, as their name suggests, but also on lymphocytes (2, 3) and basophils (4, 5), and that MCP-2, MCP-3 and MCP-4 are potent attractants for eosinophils (6–8).

Eosinophilia and tissue infiltration by eosinophils are frequently observed in allergic inflammation and parasitic diseases (9). The mechanisms by which these cells are recruited and activated is widely studied because of the pathological consequences resulting from the release of their phlogogenic and cytotoxic products. The challenge is to understand the selectivity of the chemotactic process and to develop efficient inhibitors. Several factors have been proposed as eosinophil attractants such as the anaphylatoxin C5a (10), platelet-activating factor (11), and more recently RANTES (12) and IL-16 (13). None of these stimuli is selective, however, and the discovery of eotaxin, which was originally shown to attract only eosinophils and to be specific for a single chemokine receptor, CCR3 (14–16), was greeted as a promising advance (17).

Within a large-scale sequencing and expression program for the discovery of new chemokines, we have recently identified MCP-4, a CC chemokine with powerful effects on eosinophils (8). In this paper, we describe a chemokine that is also active on eosinophils and is functionally very similar to eotaxin. It attracts and activate human eosinophils and basophils via the eotaxin receptor, CCR3, and has no activity on other leukocytes. Because of these properties, we have named the novel chemokine eotaxin-2.

	Materials and Methods

Top Abstract Materials and Methods Results and Discussion References

 
Cloning, Expression, Purification and Analysis.
The EST representing CKβ-6 cDNA was identified in the database of Human Genome Sciences Inc. (Rockville, MD) on the basis of the CC motif and the homolgy to known CC chemokines (18). The cDNA was isolated from a library derived from activated human monocytes, and the mature protein was expressed in Sf9 insect cells (CRL 1711; American Type Culture Collection, Rockville, MD). Purification was performed by cation exchange, heparin affinity, and size exclusion chromatograpy (poros 50 HS, poros 20 HE1; Perseptive Biosystem; and Sephacryl S200 HR; Pharmacia) in the presence of protease inhibitors (20 mg/ml Pefabloc SC; Boehringer Mannheim, 1 mg/ml leupeptin, 1 mg/ml E64, and 1 mM EDTA). The purified protein was analyzed by laser desorption mass spectrometry (matrix-assisted laser desorption ionization-time of flight) and by Edman degradation after partial proteolysis with the endoprotease GluC (Boehringer Mannheim).

Chemokines.
Eotaxin, MCP-3, MCP-4, RANTES, and MIP-1 were used as standards. MCP-4 was cloned and expressed as described previously (8), and the other chemokines were chemically synthesized by Dr. I. Clark-Lewis (Biomedical Research Centre, University of British Columbia, Vancouver, Canada) (19).

CCR3-blocking Antibody.
The anti-CCR3 monoclonal antibody 7B11 which selectively blocks the eotaxin receptor (20) was kindly provided by Dr. Charles Mackay (LeukoSite Inc., Cambridge, MA).

Cells.
Monocytes (21), lymphocytes (3), and neutrophils (22) were isolated from donor blood buffy coats. The lymphocytes were cultured in the presence of IL-2 as previously described (3). Eosinophils (12) and basophils (23, 24) were purified from the venous blood of healthy volunteers. The eosinophil preparations were >95% pure and the basophil preparations consisted of 70– 80% basophils and 20–30% lymphocytes.

[Ca²⁺]_i Changes.
Changes in the cytosolic free Ca²⁺ concentration ([Ca²⁺]_i) were assayed in monocytes, eosinophils, lymphocytes, and neutrophils loaded with Fura-2 (25). Receptor desensitization was tested by monitoring [Ca²⁺]_i changes in response to sequential stimulation with chemokines (21).

In Vitro Chemotaxis.
Chemotaxis was assessed in 48-well chambers (Neuro Probe, Cabin John, MD) using polyvinylpyrrolidone-free polycarbonate membranes (Nucleopore, Neuro Probe, Cabin John, MD) with 5-µm pores for eosinophils, basophils, neutrophils and monocytes, and 3-µm pores for lymphocytes (3, 6). Cell suspensions and chemokine dilutions were made in RPMI 1640 supplemented with 20 mM Hepes, pH 7.4, and 1% pasteurized plasma protein solution (Central Laboratory of the Swiss Red Cross). Migration was allowed to proceed for 60 min at 37°C in 5% CO₂. The membrane was then removed, washed on the upper side with PBS, fixed, and stained. All assays were done in triplicate, and the migrated cells were counted in five randomly selected fields at 1,000-fold magnification. Spontaneous migration was determined in the absence of chemoattractant.

Histamine and Leukotriene C₄ (LTC4) Release.
Basophils (0.1– 0.3 x 10⁶ cells/ml) in 20 mM Hepes, pH 7.4, containing 125 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂, 0.5 mM glucose and 0.025% BSA were warmed to 37°C, primed with 10 ng/ml IL-3 for 5 min, and then challenged with a chemokine. The reaction was stopped on ice after 20 min and histamine and LTC₄ were measured in the supernatants (26). Histamine release was expressed as percent of the total cellular content (determined after cell lysis). LTC₄ generation was expressed in ng per 10⁶ basophils.

Enzyme Release.
N-acetyl-β-D-glucosaminidase release was assayed in monocytes (21) and elastase release in neutrophils (22) exactly as described previously.

In Vivo Activity.
A male rhesus monkey of 7.5 kg was anesthesized by injection of 10 mg/kg Ketamine (Ketalar, Parke Davis) i.m. and 15 mg/kg Na Thiopental (Pentotal, Abbott) i.v. The chemokines (100 pmol eotaxin, 100 and 1,000 pmol eotaxin-2 in 100 µl pyrogen-free isotonic saline) were then administered intradermally on the back, and full skin thickness punch biopsies of 8-mm diameter were taken from the injection sites after 4 h. The biopsies were fixed in formalin, embedded in paraffin, and 5-µm sections were prepared. The sections were stained with Giemsa solution or hematoxylin and eosin, and the eosinophil infiltrates were evaluated by two independent observers. In each section, eosinophils were counted at a magnification of 630x in five randomly selected fields including a postcapillary venule, using a grid of 0.19 x 0.19 mm, and the number of eosinophils per mm² was calculated. Photographs were taken at a magnification of 1,000x with a Nikon Microphot microscope (Nikon AG, Switzerland).

	Results and Discussion

Top Abstract Materials and Methods Results and Discussion References

 
Eotaxin-2 Structure.
The purified material contained a protein of 8.5 kD, as judged on SDS-PAGE. The material was treated with GluC under conditions ensuring cleavage COOH-terminally of glutamic acid, and three fragments were obtained. The first two were homogeneous and extended from residue 1 to 18 and 19 to 54, respectively, while the third showed some COOH-terminal heterogeneity. Sequencing and mass spectrometry revealed tree COOH-terminally truncated forms consisting of residues 55–73, 55–75, and 55–76 in addition to the main form extending from residue 55 to 78 (Fig. 1). The mass of the 78-residue form of eotaxin-2 is 8,778.3 and the amino acid identities to reference chemokines were 43% for MCP-4, 42% for MIP-1, 39% for MCP-3 and eotaxin, and 32% for RANTES. Since the four COOH-terminal variants could not be separated all tests were performed with the mixture. The sequence shown in Fig. 1 corresponds to the cDNA-deduced sequence of the chemokine MPIF-2 that was shown to inhibit the proliferation of myeloid progenitors (18), except for two substitutions, Ala³⁵ for Gly and Ser⁴⁷ for Phe.

View larger version (7K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Amino acid sequences of eotaxin-2 aligned with eotaxin, MCP-3, MCP-4, MIP-1, and RANTES. Identical amino acids are indicated by a hyphen. The sites of COOH-terminal truncation leading to the shorter variants are indicated by arrowheads.

 
Leukocyte Responses and Receptor Usage.
[Ca²⁺]_i changes, were monitored in blood leukocytes after stimulation with 1 to 1,000 nM eotaxin-2. A marked, concentration-dependent effect was observed on eosinophils whereas neutrophils, monocytes and T lymphocytes did not respond. Desensitization experiments were then performed with eosinophils to gain information on receptor selectivity. As shown in Fig. 2, eosinophil stimulation with eotaxin-2 abrogated the response to eotaxin, attenuated the responses to MCP-3 and RANTES, but did not appreciably affect the response to MIP-1. In agreement with these results the [Ca²⁺]_i rise induced by eotaxin-2 was abrogated by prior stimulation with eotaxin, decreased by stimulation with RANTES or MCP-3, but was not affected by MIP-1. Cross-desensititzation was also observed between eotaxin-2 and MCP-4 (data not shown). These results suggest that eotaxin-2 is a selective agonist for eosinophils. The complete cross-desensitization between eotaxin-2 and eotaxin indicates that both chemokines act mainly, if not exclusively, via CCR3. This conclusion is in agreement with the partial desensitization of the responses to RANTES and MCP-3, which are known to interact with at least two additional receptors, CCR1 and CCR2. The lack desensitization of the response to MIP-1, on the other hand rules out an interaction of eotaxin-2 with CCR1.

View larger version (17K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Cross-desensitization of human blood eosinophils. Fura2–loaded cells were stimulated sequentially at 90-s intervals with 50 nM eotaxin-2 and another CC chemokine at the same concentration, and [Ca2+]i dependent fluorescence changes were recorded. The tracings are representative for three separate experiments performed under identical conditions with cells from different donors.

 
In Vitro Chemotaxis.
As shown in Fig. 3, eotaxin-2 was a highly effective attractant for eosinophils and basophils. The concentration dependence was typically bimodal, and the overall effect was similar to that of eotaxin. Maximum migration was reached at 100 nM eotaxin-2 and 10 nM eotaxin which thus appears to be more potent. When the assay was performed in the presence of the anti-CCR3 antibody, eosinophil and basophil chemotaxis toward either eotaxin or eotaxin-2 was completely prevented, indicating that they both acted exclusively via CCR3. Eotaxin-2, like eotaxin, did not induce migration of neutrophils, monocytes and T lymphocytes, which is in agreement with the lack of Ca²⁺ mobilization observed in these cells.

View larger version (27K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Chemotactic responses of human blood eosinophils and basophils to eotaxin and eotaxin-2, in the presence (open symbols) or absence (closed symbols) of 10 µg/ml anti-CCR3 added to the cells 10 min before loading into the chemotaxis chamber. Numbers of migrating cells per five high power fields are given. One out of three similar experiments performed with cells from different donors is shown.

 
Histamine and LTC₄ Release.
In view of the marked chemotactic activity toward basophils, the effect of eotaxin and eotaxin-2 as inducers of release was determined (Fig. 4). Both chemokines induced a similar release of histamine and peptido leukotrienes in IL-3 pretreated basophils from several unselected donors. The curves relating effect to concentration show that eotaxin was somewhat more potent than eotaxin-2 in particular as inducer of LTC₄ release. Similar release responses were obtained with RANTES and MIP-1 (data not shown). In agreement with the data of the chemotaxis assays, mediator release induced by eotaxin and eotaxin-2 was markedly inhibited by pretreatment of the cells with the anti-CCR3 antibody.

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Figure 4 (A and B) Histamine and LTC4 release by basophils pretreated with IL-3 in response to increasing concentrations of eotaxin and eotaxin-2. Each symbol represents mean values from four experiments performed with cells from different donors. (C and D) Histamine and LTC4 release by IL-3 pretreated basophils after stimulation with 100 nM eotaxin or eotaxin-2 in the presence (open columns) or absence (filled columns) of anti-CCR3. Mean ± SEM of three experiments performed with basophils from different donors.

 
Effects In Vivo.
The ability of eotaxin-2 to act as chemoattractant in vivo was examined in a rhesus monkey in comparison with eotaxin. As shown in Fig. 5 A, 4 h after injection of 100 pmol per site both chemokines induced a similar, marked eosinophil infiltration whereas the vehicle alone had no effect. The number of infiltrating eosinophils was 50% higher at sites where 1,000 pmol eotaxin-2 was applied. The effect is remarkable because the monkey used in this experiment had a low blood eosinophil count (0.7% of total leukocytes). As shown by representative micrographs, several infiltrating eosinophils can be recognized by the characteristic nucleus and the Giemsa staining of the granules. They are found in the vicinity of postcapillary venules (Fig. 5, B and C) and in association with the venular wall (Fig. 5 C).

View larger version (278K): [in this window] [in a new window] [Download PPT slide]   Figure 5 (A) In vivo infiltration of eosinophils. A rhesus monkey received intradermal injections of eotaxin-2 (100 or 1,000 pmol per site), eotaxin (100 pmol per site) or pyrogen-free isotonic saline. After 4 h, punch biopsies were taken and processed for histology. Eosinophils were counted on sections stained with hematoxylin and eosin (five fields per section) in areas including postcapillary venules. (B) Micrograph of a skin site 4 h after injection of 100 pmol eotaxin-2, stained with Giemsa solution. Clearly identifiable eosinophils are seen near the inset; one is seen in contact with the venule wall. (C) Micrograph of a skin site 4 h after injection of 1,000 pmol eotaxin-2, stained with hemaotxylin and eosin. Two eosinophils are within the venule wall (see also inset) and others are in the lumen and in the tissue.

 
This paper describes a chemokine which we have termed eotaxin-2 because its function is perfectly analogous to that of eotaxin. Both chemokines activate and attract eosinophils and basophils, but no other leukocytes, and appear to act exclusively via CCR3. It must be mentioned, however, that a virtually identical chemokine, MPIF-2, was reported to inhibit colony formation by myeloid progenitor cells (18). The functional similarity between eotaxin and eotaxin-2 is astonishing because these chemokines share only 39% identical amino acids. In addition, they differ almost completely within the short NH₂-terminal sequence preceding the first cysteine, which has been identified as the receptor triggering region of several chemokines (27). It is well established that all CXC chemokines that activate neutrophils via the IL-8 receptors, CXCR1 and CXCR2, share a conserved Glu-Leu-Arg motif preceding the first cysteine that tolerates only minimal substitutions (28, 29), and it has been shown more recently that CC chemokines drastically lose activity toward monocytes (1) and basophils (27, 30) upon deletion of as few as one or two NH₂-terminal amino acids. Yet the present findings show selective activation of the same receptor, CCR3, by two chemokines that have only one common residue (Pro-4 of eotaxin-2 corresponding to Pro-6 of eotaxin) in the presumed receptor triggering domain. The eotaxin sequence is actually much more similar (60% identity) to that of MCP-3, which binds to CCR3, but also to CCR1 and CCR2 and even to MCP-1, a selective ligand for CCR2, which is inactive on eosinophils.

Eotaxin is an unusually selective chemokine (17). It was discovered as attractant for eosinophils in the bronchoalveolar lavage fluid obtained in an experimental model for lung allergy in guinea-pigs (17, 31) and subsequently shown to occur in mice (32) and humans (15) as well. The present discovery of a chemokine that shares with eotaxin receptor specificity, in vitro activities on eosinophils and basophils, and the ability to elicit eosinophil infiltration in vivo reveals the existence of a mechanism for the concomitant and selective recruitment of the two types of granulocytes that are characteristic of allergic inflammation.

	Acknowledgments

 
We thank Dr. Ian Clark-Lewis (Biomedical Research Center, University of British Columbia, Vancouver, Canada) for the supply of reference chemokines, Dr. Gianni Garotta (Human Genome Sciences Inc., Rockville, MD) for supplying a purified preparation of CKβ-6. Dr. Charles Mackay (LeukoSite Inc., Cambridge, MA) for the anti-CCR3 monoclonal antibody 7B11, Dr. Antoinette Wetterwald (Institute of Pathophysiology, University of Bern, Switzerland) for advice on histology, and Dr. Beatrice Dewald (Theodor Kocher Institute, University of Bern, Switzerland) for critical reading of the manuscript. We acknowledge the expert technical assistance of Andrea Blaser and Silvia Rihs. We are grateful to Dr. Pedro Cuevas and Dr. WolfGeorg Forssmann (Ramon y Cajal Hospital, Madrid, Spain) for the application in vivo. The experiment was approved by the Animal Ethical Committee of the Hospital and carried according to the European Union guidelines for reducing pain and discomfort to experimental animals.

Submitted: 7 March 1997
Revised: 18 April 1997

	References

Top Abstract Materials and Methods Results and Discussion References

 

1 Baggiolini M, Dewald B & Moser B. Interleukin-8 and related chemotactic cytokines—CXC and CC chemokines, Adv Immunol, 1994, 55, 97–179.[Medline]

2 Carr MW, Roth SJ, Luther E, Rose SS & Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant, Proc Natl Acad Sci USA, 1994, 91, 3652–3656.[Abstract/Free Full Text]

3 Loetscher P, Seitz M, Baggiolini M & Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes, J Exp Med, 1996, 184, 569–577.[Abstract/Free Full Text]

4 Kuna P, Reddigari SR, Rucinski D, Oppenheim JJ & Kaplan AP. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils, J Exp Med, 1992, 175, 489–493.[Abstract/Free Full Text]

5 Alam R, Lett-Brown MA, Forsythe PA, AndersonWalters DJ, Kenamore C, Kormos C & Grant JA. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils, J Clin Invest, 1992, 89, 723–728.[Medline]

6 Weber M, Uguccioni M, Ochensberger B, Baggiolini M, Clark-Lewis I & Dahinden CA. Monocyte chemotactic protein MCP-2 activates human basophil and eosinophil leukocytes similar to MCP-3, J Immunol, 1995, 154, 4166–4172.[Abstract]

7 Dahinden CA, Geiser T, Brunner T, von Tscharner V, Caput D, Ferrara P, Minty A & Baggiolini M. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine, J Exp Med, 1994, 179, 751–756.[Abstract/Free Full Text]

8 Uguccioni M, Loetscher P, Forssmann U, Dewald B, Li HD, Lima SH, Li YL, Kreider B, Garotta G, Thelen M & Baggiolini M. Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin, J Exp Med, 1996, 183, 2379–2384.[Abstract/Free Full Text]

9 Baggiolini M & Dahinden CA. CC chemokines in allergic inflammation, Immunol Today, 1994, 15, 127–133.[Medline]

10 Fernandez HN, Henson PM, Otani A & Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions, J Immunol, 1978, 120, 109–115.[Abstract/Free Full Text]

11 Wardlaw AJ, Moqbel R, Cromwell O & Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils, J Clin Invest, 1986, 78, 1701–1706.[Medline]

12 Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ & Dahinden CA. RANTES and macrophage inflammatory protein 1 induce the migration and activation of normal human eosinophil granulocytes, J Exp Med, 1992, 176, 1489–1495.[Abstract/Free Full Text]

13 Rand TH, Cruikshank WW, Center DM & Weller PF. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4binding ligands elicit eosinophil migration, J Exp Med, 1991, 173, 1521–1528.[Abstract/Free Full Text]

14 Kitaura M, Nakajima T, Imai T, Harada S, Combadiere C, Tiffany HL, Murphy PM & Yoshie O. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3, J Biol Chem, 1996, 271, 7725–7730.[Abstract/Free Full Text]

15 Ponath PD, Qin SX, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi XJ, Gonzalo JA, Newman W et al.. Cloning of the human eosinophil chemoattractant, eotaxin - Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils, J Clin Invest, 1996, 97, 604–612.[Medline]

16 Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A & Springer MS. Cloning, expression, and characterization of the human eosinophil eotaxin receptor, J Exp Med, 1996, 183, 2349–2354.[Abstract/Free Full Text]

17 Baggiolini M. Eotaxin: A VIC (very important chemokine) of allergic inflammation? , J Clin Invest, 1996, 97, 587, .[Medline]

18 Patel VP, Kreider BL, Li Y, Li H, Leung K, Salcedo T, Nardelli B, Pippalla V, Gentz S, Thotakura R et al.. Molecular and functional characterization of two novel human chemokines as inhibitors of two distinct classes of myeloid progenitors, J Exp Med, 1997, 185, 1163–1172.[Abstract/Free Full Text]

19 Clark-Lewis I, Moser B, Walz A, Baggiolini M, Scott GJ & Aebersold R. Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide 2, Biochemistry, 1991, 30, 3128–3135.[Medline]

20 Heath H, Quin S, Rao P, Wu L, LaRosa GJ, Kassam N, Ponath PD & Mackay CR. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody, J Clin Invest, 1997, 99, 178–184.[Medline]

21 Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B & Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 and MIP-1β on human monocytes, Eur J Immunol, 1995, 25, 64–68.[Medline]

22 Peveri P, Walz A, Dewald B & Baggiolini M. A novel neutrophil-activating factor produced by human mononuclear phagocytes, J Exp Med, 1988, 167, 1547–1559.[Abstract/Free Full Text]

23 Bischoff SC, Krieger M, Brunner T & Dahinden CA. Monocyte chemotactic protein 1 is a potent activator of human basophils, J Exp Med, 1992, 175, 1271–1275.[Abstract/Free Full Text]

24 Bischoff SC, Krieger M, Brunner T, Rot A, von Tscharner V, Baggiolini M & Dahinden CA. RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors, Eur J Immunol, 1993, 23, 761–767.[Medline]

25 von Tscharner V, Prod'hom B, Baggiolini M & Reuter H. Ion channels in human neutrophils activated by a rise in free cytosolic calcium concentration, Nature (Lond), 1986, 324, 369–372.[Medline]

26 Bischoff SC & Dahinden CA. Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils, Blood, 1992, 79, 662–2669.

27 Baggiolini, M., B. Dewald, and B. Moser. 1997. Human chemokines: an update. Adv. Immunol. In press.

28 Clark-Lewis I, Schumacher C, Baggiolini M & Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH₂-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities, J Biol Chem, 1991, 266, 23128–23134.[Abstract/Free Full Text]

29 Gong J-H & Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH₂-terminal residues, J Exp Med, 1995, 181, 631–640.[Abstract/Free Full Text]

30 Weber M, Uguccioni M, Baggiolini M, Clark-Lewis I & Dahinden CA. Deletion of the NH₂-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant, J Exp Med, 1996, 183, 681–685.[Abstract/Free Full Text]

31 Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ & Williams TJ. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. , Biochem Biophys Res Commun, 1993, 197, 1167–1172.[Medline]

32 Rothenberg ME, Luster AD & Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression, Proc Natl Acad Sci USA, 1995, 92, 8960–8964.[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

• Yan, B M, Shaffer, E A (2009). Primary eosinophilic disorders of the gastrointestinal tract. Gut 58: 721-732 [Abstract] [Full Text]  
• Lehmann, M. H., Kastenmuller, W., Kandemir, J. D., Brandt, F., Suezer, Y., Sutter, G. (2009). Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression. J. Virol. 83: 2540-2552 [Abstract] [Full Text]  
• Kim, H.-B., Kim, C.-K., Iijima, K., Kobayashi, T., Kita, H. (2009). Protein Microarray Analysis in Patients With Asthma: Elevation of the Chemokine PARC/CCL18 in Sputum. Chest 135: 295-302 [Abstract] [Full Text]  
• Forssmann, U., Stoetzer, C., Stephan, M., Kruschinski, C., Skripuletz, T., Schade, J., Schmiedl, A., Pabst, R., Wagner, L., Hoffmann, T., Kehlen, A., Escher, S. E., Forssmann, W.-G., Elsner, J., von Horsten, S. (2008). Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo. J. Immunol. 181: 1120-1127 [Abstract] [Full Text]  
• Haley, K. J., Sunday, M. E., Porrata, Y., Kelley, C., Twomey, A., Shahsafaei, A., Galper, B., Sonna, L. A., Lilly, C. M. (2008). Ontogeny of the eotaxins in human lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L214-L224 [Abstract] [Full Text]  
• Cheadle, E. J., Riyad, K., Subar, D., Rothwell, D. G., Ashton, G., Batha, H., Sherlock, D. J., Hawkins, R. E., Gilham, D. E. (2007). Eotaxin-2 and Colorectal Cancer: A Potential Target for Immune Therapy. Clin. Cancer Res. 13: 5719-5728 [Abstract] [Full Text]  
• Voehringer, D., van Rooijen, N., Locksley, R. M. (2007). Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. J. Leukoc. Biol. 81: 1434-1444 [Abstract] [Full Text]  
• Scheicher, M. E., Teixeira, M. M., Cunha, F. Q., Teixeira, A. L. Jr, Filho, J. T., Vianna, E. O. (2007). Eotaxin-2 in sputum cell culture to evaluate asthma inflammation. Eur Respir J 29: 489-495 [Abstract] [Full Text]  
• Guedes, A. G. P., Paulin, J., Rivero-Nava, L., Kita, H., Lund, F. E., Kannan, M. S. (2006). CD38-deficient mice have reduced airway hyperresponsiveness following IL-13 challenge. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L1286-L1293 [Abstract] [Full Text]  
• Das, A. M., Vaddi, K. G., Solomon, K. A., Krauthauser, C., Jiang, X., McIntyre, K. W., Yang, X. X., Wadman, E., Welch, P., Covington, M., Graden, D., Yeleswaram, K., Trzaskos, J. M., Newton, R. C., Mandlekar, S., Ko, S. S., Carter, P. H., Davies, P. (2006). Selective Inhibition of Eosinophil Influx into the Lung by Small Molecule CC Chemokine Receptor 3 Antagonists in Mouse Models of Allergic Inflammation. J. Pharmacol. Exp. Ther. 318: 411-417 [Abstract] [Full Text]  
• Ancuta, P., Autissier, P., Wurcel, A., Zaman, T., Stone, D., Gabuzda, D. (2006). CD16+ Monocyte-Derived Macrophages Activate Resting T Cells for HIV Infection by Producing CCR3 and CCR4 Ligands. J. Immunol. 176: 5760-5771 [Abstract] [Full Text]  
• Morokata, T., Suzuki, K., Masunaga, Y., Taguchi, K., Morihira, K., Sato, I., Fujii, M., Takizawa, S., Torii, Y., Yamamoto, N., Kaneko, M., Yamada, T., Takahashi, K., Shimizu, Y. (2006). A Novel, Selective, and Orally Available Antagonist for CC Chemokine Receptor 3. J. Pharmacol. Exp. Ther. 317: 244-250 [Abstract] [Full Text]  
• Fritz, D. K., Kerr, C., Tong, L., Smyth, D., Richards, C. D. (2006). Oncostatin-M Up-Regulates VCAM-1 and Synergizes with IL-4 in Eotaxin Expression: Involvement of STAT6. J. Immunol. 176: 4352-4360 [Abstract] [Full Text]  
• Tsuji, K., Yamamoto, S., Ou, W., Nishi, N., Kobayashi, I., Zaitsu, M., Muro, E., Sadakane, Y., Ichimaru, T., Hamasaki, Y. (2005). dsRNA enhances eotaxin-3 production through interleukin-4 receptor upregulation in airway epithelial cells. Eur Respir J 26: 795-803 [Abstract] [Full Text]  
• Min, J.-W., Jang, A.-S., Park, S.-M., Lee, S.-H., Lee, J.-H., Park, S.-W., Park, C.-S. (2005). Comparison of Plasma Eotaxin Family Level in Aspirin-Induced and Aspirin-Tolerant Asthma Patients. Chest 128: 3127-3132 [Abstract] [Full Text]  
• Ulfman, L. H., Alblas, J., van Aalst, C. W., Zwaginga, J. J., Koenderman, L. (2005). Differences in Potency of CXC Chemokine Ligand 8-, CC Chemokine Ligand 11-, and C5a-Induced Modulation of Integrin Function on Human Eosinophils. J. Immunol. 175: 6092-6099 [Abstract] [Full Text]  
• Yamamoto, S., Kobayashi, I., Tsuji, K., Nishi, N., Muro, E., Miyazaki, M., Zaitsu, M., Inada, S., Ichimaru, T., Hamasaki, Y. (2004). Upregulation of Interleukin-4 Receptor by Interferon-{gamma}: Enhanced Interleukin-4-Induced Eotaxin-3 Production in Airway Epithelium. Am. J. Respir. Cell Mol. Bio. 31: 456-462 [Abstract] [Full Text]  
• Forssmann, U., Hartung, I., Balder, R., Fuchs, B., Escher, S. E., Spodsberg, N., Dulkys, Y., Walden, M., Heitland, A., Braun, A., Forssmann, W.-G., Elsner, J. (2004). n-Nonanoyl-CC Chemokine Ligand 14, a Potent CC Chemokine Ligand 14 Analogue That Prevents the Recruitment of Eosinophils in Allergic Airway Inflammation. J. Immunol. 173: 3456-3466 [Abstract] [Full Text]  
• Kodali, R. B., Kim, W. J.H., Galaria, I. I., Miller, C., Schecter, A. D., Lira, S. A., Taubman, M. B. (2004). CCL11 (Eotaxin) Induces CCR3-Dependent Smooth Muscle Cell Migration. Arterioscler. Thromb. Vasc. Bio. 24: 1211-1216 [Abstract] [Full Text]  
• Jaruga, B., Hong, F., Sun, R., Radaeva, S., Gao, B. (2003). Crucial Role of IL-4/STAT6 in T Cell-Mediated Hepatitis: Up-Regulating Eotaxins and IL-5 and Recruiting Leukocytes. J. Immunol. 171: 3233-3244 [Abstract] [Full Text]  
• Jinquan, T., Jacobi, H. H., Jing, C., Millner, A., Sten, E., Hviid, L., Anting, L., Ryder, L. P., Glue, C., Skov, P. S., Jarman, E., Lamberth, K., Malling, H.-J., Poulsen, L. K. (2003). CCR3 Expression Induced by IL-2 and IL-4 Functioning as a Death Receptor for B Cells. J. Immunol. 171: 1722-1731 [Abstract] [Full Text]  
• Shin, H. D., Kim, L. H., Park, B. L., Jung, J. H., Kim, J. Y., Chung, I.-Y., Kim, J. S., Lee, J. H., Chung, S. H., Kim, Y. H., Park, H.-S., Choi, J. H., Lee, Y. M., Park, S. W., Choi, B. W., Hong, S.-J., Park, C.-S. (2003). Association of Eotaxin gene family with asthma and serum total IgE. Hum Mol Genet 12: 1279-1285 [Abstract] [Full Text]  
• Langdon, C., Kerr, C., Tong, L., Richards, C. D. (2003). Oncostatin M Regulates Eotaxin Expression in Fibroblasts and Eosinophilic Inflammation in C57BL/6 Mice. J. Immunol. 170: 548-555 [Abstract] [Full Text]  
• Uchida, T., Suto, H., Ra, C., Ogawa, H., Kobata, T., Okumura, K. (2002). Preferential expression of Th2-type chemokine and its receptor in atopic dermatitis. Int Immunol 14: 1431-1438 [Abstract] [Full Text]  
• Beaulieu, S., Robbiani, D. F., Du, X., Rodrigues, E., Ignatius, R., Wei, Y., Ponath, P., Young, J. W., Pope, M., Steinman, R. M., Mojsov, S. (2002). Expression of a Functional Eotaxin (CC Chemokine Ligand 11) Receptor CCR3 by Human Dendritic Cells. J. Immunol. 169: 2925-2936 [Abstract] [Full Text]  
• Badewa, A.P., Hudson, C.E., Heiman, A.S. (2002). Regulatory Effects of Eotaxin, Eotaxin-2, and Eotaxin-3 on Eosinophil Degranulation and Superoxide Anion Generation. Exp. Biol. Med. 227: 645-651 [Abstract] [Full Text]  
• Menzies-Gow, A., Ying, S., Sabroe, I., Stubbs, V. L., Soler, D., Williams, T. J., Kay, A. B. (2002). Eotaxin (CCL11) and Eotaxin-2 (CCL24) Induce Recruitment of Eosinophils, Basophils, Neutrophils, and Macrophages As Well As Features of Early- and Late-Phase Allergic Reactions Following Cutaneous Injection in Human Atopic and Nonatopic Volunteers. J. Immunol. 169: 2712-2718 [Abstract] [Full Text]  
• Stubbs, V. E. L., Schratl, P., Hartnell, A., Williams, T. J., Peskar, B. A., Heinemann, A., Sabroe, I. (2002). Indomethacin Causes Prostaglandin D2-like and Eotaxin-like Selective Responses in Eosinophils and Basophils. J. Biol. Chem. 277: 26012-26020 [Abstract] [Full Text]  
• Schuh, J. M., Blease, K., Kunkel, S. L., Hogaboam, C. M. (2002). Eotaxin/CCL11 is involved in acute, but not chronic, allergic airway responses to Aspergillus fumigatus. Am. J. Physiol. Lung Cell. Mol. Physiol. 283: L198-L204 [Abstract] [Full Text]  
• Borchers, M. T., Ansay, T., DeSalle, R., Daugherty, B. L., Shen, H., Metzger, M., Lee, N. A., Lee, J. J. (2002). In vitro assessment of chemokine receptor-ligand interactions mediating mouse eosinophil migration. J. Leukoc. Biol. 71: 1033-1041 [Abstract] [Full Text]  
• Watanabe, K., Jose, P. J., Rankin, S. M. (2002). Eotaxin-2 Generation Is Differentially Regulated by Lipopolysaccharide and IL-4 in Monocytes and Macrophages. J. Immunol. 168: 1911-1918 [Abstract] [Full Text]  
• Lilly, C. M., Daugherty, B. L. (2001). A Novel LPS-Inducible CCR3 Activator . Why So Many CCR3 Ligands?. Am. J. Respir. Cell Mol. Bio. 25: 673-675 [Full Text]  
• Hoeck, J., Woisetschlager, M. (2001). Activation of Eotaxin-3/CCL26 Gene Expression in Human Dermal Fibroblasts Is Mediated by STAT6. J. Immunol. 167: 3216-3222 [Abstract] [Full Text]  
• Bandeira-Melo, C., Herbst, A., Weller, P. F. (2001). Eotaxins . Contributing to the Diversity of Eosinophil Recruitment and Activation. Am. J. Respir. Cell Mol. Bio. 24: 653-657 [Full Text]  
• Berkman, N., Ohnona, S., Chung, F. K., Breuer, R. (2001). Eotaxin-3 but Not Eotaxin Gene Expression Is Upregulated in Asthmatics 24 Hours after Allergen Challenge. Am. J. Respir. Cell Mol. Bio. 24: 682-687 [Abstract] [Full Text]  
• Ogilvie, P., Bardi, G., Clark-Lewis, I., Baggiolini, M., Uguccioni, M. (2001). Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 97: 1920-1924 [Abstract] [Full Text]  
• Heinemann, A., Hartnell, A., Stubbs, V. E. L., Murakami, K., Soler, D., LaRosa, G., Askenase, P. W., Williams, T. J., Sabroe, I. (2000). Basophil Responses to Chemokines Are Regulated by Both Sequential and Cooperative Receptor Signaling. J. Immunol. 165: 7224-7233 [Abstract] [Full Text]  
• Aust, G., Simchen, C., Heider, U., Hmeidan, F. A., Blumenauer, V., Spanel-Borowski, K. (2000). Eosinophils in the human corpus luteum: the role of RANTES and eotaxin in eosinophil attraction into periovulatory structures. Mol Hum Reprod 6: 1085-1091 [Abstract] [Full Text]  
• Detheux, M., Standker, L., Vakili, J., Munch, J., Forssmann, U., Adermann, K., Pohlmann, S., Vassart, G., Kirchhoff, F., Parmentier, M., Forssmann, W.-G. (2000). Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties. JEM 192: 1501-1508 [Abstract] [Full Text]  
• Zimmermann, N., Hogan, S. P., Mishra, A., Brandt, E. B., Bodette, T. R., Pope, S. M., Finkelman, F. D., Rothenberg, M. E. (2000). Murine Eotaxin-2: A Constitutive Eosinophil Chemokine Induced by Allergen Challenge and IL-4 Overexpression. J. Immunol. 165: 5839-5846 [Abstract] [Full Text]  
• Tachimoto, H., Burdick, M. M., Hudson, S. A., Kikuchi, M., Konstantopoulos, K., Bochner, B. S. (2000). CCR3-Active Chemokines Promote Rapid Detachment of Eosinophils from VCAM-1 In Vitro. J. Immunol. 165: 2748-2754 [Abstract] [Full Text]  
• Murdoch, C., Finn, A. (2000). Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032-3043 [Abstract] [Full Text]  
• Blumenthal, R. D., Samoszuk, M., Taylor, A. P., Brown, G., Alisauskas, R., Goldenberg, D. M. (2000). Degranulating Eosinophils in Human Endometriosis. Am. J. Pathol. 156: 1581-1588 [Abstract] [Full Text]  
• Matsushita, N., Nishi, N., Seki, M., Matsumoto, R., Kuwabara, I., Liu, F.-T., Hata, Y., Nakamura, T., Hirashima, M. (2000). Requirement of Divalent Galactoside-binding Activity of Ecalectin/Galectin-9 for Eosinophil Chemoattraction. J. Biol. Chem. 275: 8355-8360 [Abstract] [Full Text]  
• Kampen, G. T., Stafford, S., Adachi, T., Jinquan, T., Quan, S., Grant, J. A., Skov, P. S., Poulsen, L. K., Alam, R. (2000). Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95: 1911-1917 [Abstract] [Full Text]  
• Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., Power, C. A. (2000). International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol. Rev. 52: 145-176 [Abstract] [Full Text]  
• Nibbs, R. J. B., Salcedo, T. W., Campbell, J. D. M., Yao, X.-T., Li, Y., Nardelli, B., Olsen, H. S., Morris, T. S., Proudfoot, A. E. I., Patel, V. P., Graham, G. J. (2000). C-C Chemokine Receptor 3 Antagonism by the {beta}-Chemokine Macrophage Inflammatory Protein 4, a Property Strongly Enhanced by an Amino-Terminal Alanine-Methionine Swap. J. Immunol. 164: 1488-1497 [Abstract] [Full Text]  
• Camarda, G., Spinetti, G., Bernardini, G., Mair, C., Davis-Poynter, N., Capogrossi, M. C., Napolitano, M. (1999). The Equine Herpesvirus 2 E1 Open Reading Frame Encodes a Functional Chemokine Receptor. J. Virol. 73: 9843-9848 [Abstract] [Full Text]  
• Ying, S., Meng, Q., Zeibecoglou, K., Robinson, D. S., Macfarlane, A., Humbert, M., Kay, A. B. (1999). Eosinophil Chemotactic Chemokines (Eotaxin, Eotaxin-2, RANTES, Monocyte Chemoattractant Protein-3 (MCP-3), and MCP-4), and C-C Chemokine Receptor 3 Expression in Bronchial Biopsies from Atopic and Nonatopic (Intrinsic) Asthmatics. J. Immunol. 163: 6321-6329 [Abstract] [Full Text]  
• Ying, S., Robinson, D. S., Meng, Q., Barata, L. T., McEuen, A. R., Buckley, M. G., Walls, A. F., Askenase, P. W., Kay, A. B. (1999). C-C Chemokines in Allergen-Induced Late-Phase Cutaneous Responses in Atopic Subjects: Association of Eotaxin with Early 6-Hour Eosinophils, and of Eotaxin-2 and Monocyte Chemoattractant Protein-4 with the Later 24-Hour Tissue Eosinophilia, and Relationship to Basophils and Other C-C Chemokines (Monocyte Chemoattractant Protein-3 and RANTES). J. Immunol. 163: 3976-3984 [Abstract] [Full Text]  
• Kitaura, M., Suzuki, N., Imai, T., Takagi, S., Suzuki, R., Nakajima, T., Hirai, K., Nomiyama, H., Yoshie, O. (1999). Molecular Cloning of a Novel Human CC Chemokine (Eotaxin-3) That Is a Functional Ligand of CC Chemokine Receptor 3. J. Biol. Chem. 274: 27975-27980 [Abstract] [Full Text]  
• Rothenberg, M. E. (1999). Eotaxin . An Essential Mediator of Eosinophil Trafficking into Mucosal Tissues. Am. J. Respir. Cell Mol. Bio. 21: 291-295 [Full Text]  
• Chung, K F, Barnes, P J (1999). Cytokines in asthma. Thorax 54: 825-857 [Full Text]  
• Devouassoux, G., Metcalfe, D. D., Prussin, C. (1999). Eotaxin Potentiates Antigen-Dependent Basophil IL-4 Production. J. Immunol. 163: 2877-2882 [Abstract] [Full Text]  
• HISADA, T., SALMON, M., NASUHARA, Y., CHUNG, K. F. (1999). Cysteinyl-leukotrienes Partly Mediate Eotaxin-induced Bronchial Hyperresponsiveness and Eosinophilia in IL-5 Transgenic Mice. Am. J. Respir. Crit. Care Med. 160: 571-575 [Abstract] [Full Text]  
• Jahnsen, F. L., Haye, R., Gran, E., Brandtzaeg, P., Johansen, F.-E. (1999). Glucocorticosteroids Inhibit mRNA Expression for Eotaxin, Eotaxin-2, and Monocyte-Chemotactic Protein-4 in Human Airway Inflammation with Eosinophilia. J. Immunol. 163: 1545-1551 [Abstract] [Full Text]  
• Shinkai, A., Yoshisue, H., Koike, M., Shoji, E., Nakagawa, S., Saito, A., Takeda, T., Imabeppu, S., Kato, Y., Hanai, N., Anazawa, H., Kuga, T., Nishi, T. (1999). A Novel Human CC Chemokine, Eotaxin-3, Which Is Expressed in IL-4-Stimulated Vascular Endothelial Cells, Exhibits Potent Activity Toward Eosinophils. J. Immunol. 163: 1602-1610 [Abstract] [Full Text]  
• Giembycz, M. A., Lindsay, M. A. (1999). Pharmacology of the Eosinophil. Pharmacol. Rev. 51: 213-340 [Abstract] [Full Text]  
• Hisada, T., Hellewell, P. G., Teixeira, M. M., Malm, M. G. K., Salmon, M., Huang, T.-J., Fan Chung, K. (1999). alpha 4 Integrin-Dependent Eotaxin Induction of Bronchial Hyperresponsiveness and Eosinophil Migration in Interleukin-5 Transgenic Mice. Am. J. Respir. Cell Mol. Bio. 20: 992-1000 [Abstract] [Full Text]  
• Struyf, S., Proost, P., Schols, D., De Clercq, E., Opdenakker, G., Lenaerts, J.-P., Detheux, M., Parmentier, M., De Meester, I., Scharpe, S., Van Damme, J. (1999). CD26/Dipeptidyl-Peptidase IV Down-Regulates the Eosinophil Chemotactic Potency, But Not the Anti-HIV Activity of Human Eotaxin by Affecting Its Interaction with CC Chemokine Receptor 3. J. Immunol. 162: 4903-4909 [Abstract] [Full Text]  
• Teruya-Feldstein, J., Jaffe, E. S., Burd, P. R., Kingma, D. W., Setsuda, J. E., Tosato, G. (1999). Differential Chemokine Expression in Tissues Involved by Hodgkin's Disease: Direct Correlation of Eotaxin Expression and Tissue Eosinophilia. Blood 93: 2463-2470 [Abstract] [Full Text]  
• Jinquan, T., Quan, S., Feili, G., Larsen, C. G., Thestrup-Pedersen, K. (1999). Eotaxin Activates T Cells to Chemotaxis and Adhesion Only if Induced to Express CCR3 by IL-2 Together with IL-4. J. Immunol. 162: 4285-4292 [Abstract] [Full Text]  
• Sabroe, I., Hartnell, A., Jopling, L. A., Bel, S., Ponath, P. D., Pease, J. E., Collins, P. D., Williams, T. J. (1999). Differential Regulation of Eosinophil Chemokine Signaling Via CCR3 and Non-CCR3 Pathways. J. Immunol. 162: 2946-2955 [Abstract] [Full Text]  
• Barnes, P. J., Chung, K. F., Page, C. P. (1998). Inflammatory Mediators of Asthma: An Update. Pharmacol. Rev. 50: 515-596 [Abstract] [Full Text]  
• Sabroe, I., Conroy, D. M., Gerard, N. P., Li, Y., Collins, P. D., Post, T. W., Jose, P. J., Williams, T. J., Gerard, C. J., Ponath, P. D. (1998). Cloning and Characterization of the Guinea Pig Eosinophil Eotaxin Receptor, C-C Chemokine Receptor-3: Blockade Using a Monoclonal Antibody In Vivo. J. Immunol. 161: 6139-6147 [Abstract] [Full Text]  
• Yang, Y., Loy, J., Ryseck, R.-P., Carrasco, D., Bravo, R. (1998). Antigen-Induced Eosinophilic Lung Inflammation Develops in Mice Deficient in Chemokine Eotaxin. Blood 92: 3912-3923 [Abstract] [Full Text]  
• Andrew, D. P., Chang, M.-s., McNinch, J., Wathen, S. T., Rihanek, M., Tseng, J., Spellberg, J. P., Elias, C. G. III (1998). STCP-1 (MDC) CC Chemokine Acts Specifically on Chronically Activated Th2 Lymphocytes and Is Produced by Monocytes on Stimulation with Th2 Cytokines IL-4 and IL-13. J. Immunol. 161: 5027-5038 [Abstract] [Full Text]  
• Huang, W.-W., Garcia-Zepeda, E. A., Sauty, A., Oettgen, H. C., Rothenberg, M. E., Luster, A. D. (1998). Molecular and Biological Characterization of the Murine Leukotriene B4 Receptor Expressed on Eosinophils. JEM 188: 1063-1074 [Abstract] [Full Text]  
• Kim, C. H., Pelus, L. M., White, J. R., Broxmeyer, H. E. (1998). Macrophage-Inflammatory Protein-3{beta}/EBI1-Ligand Chemokine/CK{beta}-11, a CC Chemokine, Is a Chemoattractant with a Specificity for Macrophage Progenitors Among Myeloid Progenitor Cells. J. Immunol. 161: 2580-2585 [Abstract] [Full Text]  
• Crump, M. P., Rajarathnam, K., Kim, K.-S., Clark-Lewis, I., Sykes, B. D. (1998). Solution Structure of Eotaxin, a Chemokine That Selectively Recruits Eosinophils in Allergic Inflammation. J. Biol. Chem. 273: 22471-22479 [Abstract] [Full Text]  
• Matsumoto, R., Matsumoto, H., Seki, M., Hata, M., Asano, Y., Kanegasaki, S., Stevens, R. L., Hirashima, M. (1998). Human Ecalectin, a Variant of Human Galectin-9, Is a Novel Eosinophil Chemoattractant Produced by T Lymphocytes. J. Biol. Chem. 273: 16976-16984 [Abstract] [Full Text]  
• Rothenberg, M. E. (1998). Eosinophilia. NEJM 338: 1592-1600 [Full Text]  
• Yoshida, R., Nagira, M., Kitaura, M., Imagawa, N., Imai, T., Yoshie, O. (1998). Secondary Lymphoid-tissue Chemokine Is a Functional Ligand for the CC Chemokine Receptor CCR7. J. Biol. Chem. 273: 7118-7122 [Abstract] [Full Text]  
• Kim, C. H., Pelus, L. M., White, J. R., Applebaum, E., Johanson, K., Broxmeyer, H. E. (1998). CK{beta}-11/Macrophage Inflammatory Protein-3{beta}/EBI1-Ligand Chemokine Is an Efficacious Chemoattractant for T and B Cells. J. Immunol. 160: 2418-2424 [Abstract] [Full Text]  
• Sallusto, F., Mackay, C. R., Lanzavecchia, A. (1997). Selective Expression of the Eotaxin Receptor CCR3 by Human T Helper 2 Cells. Science 277: 2005-2007 [Abstract] [Full Text]  
• Ye, J., Kohli, L. L., Stone, M. J. (2000). Characterization of Binding between the Chemokine Eotaxin and Peptides Derived from the Chemokine Receptor CCR3. J. Biol. Chem. 275: 27250-27257 [Abstract] [Full Text]  
• White, J. R., Lee, J. M., Dede, K., Imburgia, C. S., Jurewicz, A. J., Chan, G., Fornwald, J. A., Dhanak, D., Christmann, L. T., Darcy, M. G., Widdowson, K. L., Foley, J. J., Schmidt, D. B., Sarau, H. M. (2000). Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration. J. Biol. Chem. 275: 36626-36631 [Abstract] [Full Text]  
• Mayer, M. R., Stone, M. J. (2001). Identification of Receptor Binding and Activation Determinants in the N-terminal and N-loop Regions of the CC Chemokine Eotaxin. J. Biol. Chem. 276: 13911-13916 [Abstract] [Full Text]  
• Sabroe, I., Peck, M. J., Van Keulen, B. J., Jorritsma, A., Simmons, G., Clapham, P. R., Williams, T. J., Pease, J. E. (2000). A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3. POTENT INHIBITION OF EOSINOPHIL FUNCTION AND CCR3-MEDIATED HIV-1 ENTRY. J. Biol. Chem. 275: 25985-25992 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF, 171K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Forssmann, U. Articles by Baggiolini, M. Search for Related Content PubMed PubMed Citation Articles by Forssmann, U. Articles by Baggiolini, M. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Social Bookmarking                            What's this?